-
12:36:30 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

Trending News

Covid-19 News LIVE

The stock market news feed is automatically updated to show the latest 50 news.
The news is in real time for GOLD users while a 15 second delay is applied for FREE users.

Become a Gold member to unlock the feed filters, voice notification and see the news without delay.

Check out our Stock Market News Today and Join our Discord

05/26/22 7:00 AM
Nasdaq : MQ
covid-19
Marqeta Study: COVID-Driven Digital Payment Adoption Likely Here to Stay for US Consumers
The pandemic ushered in a seismic shift in preferences around how consumers want to pay, bank and shop, which two years later has become commonplace and second nature, according to a new survey from Marqeta, the global modern card issuing platform. “As digital payment use exploded during the pandemic, one of the most common questions we got asked at Marqeta was...
RHEA-AI
neutral
05/26/22 7:00 AM
Nasdaq : AXLA
clinical trialcovid-19
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
Patient enrollment is complete in the prospective, placebo controlled, randomized trial conducted at the John Radcliffe Hospital at Oxford University in England. Betty Raman, British Heart Foundation Oxford Centre of Research Excellence Clinical Transition Intermediate Fellow, said,“ We have completed enrollment of the forty patients for this integral...
RHEA-AI
neutral
05/26/22 12:03 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19
Based on a review of nearly 75% of the target enrollment of 640 patients, most of which have reached 90 days, the Independent DSMB overseeing the ACTIV-3b (TESICO) study determined that evaluation of aviptadil should cease due to futility ZYESAMI® (aviptadil) was the sole remaining investigational
RHEA-AI
neutral
05/25/22 11:00 PM
Nasdaq : MQ
covid-19
Marqeta Study: Australians Lead the Way in Digital Payment Use, as Mobile Wallet Use Spikes 67 Percent Post-COVID
Australian consumers are at the forefront of mobile wallet use and adoption of digital banking tools, abandoning cash and physical payment experiences in larger numbers than the US or UK, according to a new survey from Marqeta, the global modern card issuing platform. The company’ s 2022 State of Consumer Money Movement report released today– surveying 4,076...
RHEA-AI
neutral
05/24/22 4:50 PM
Nasdaq : MICT
covid-19
MICT Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) regarding its Inability to File its Form 10-Q Due to the Impact of Strict COVID-19 Lockdown Restrictions in China on the completion of its Audit)
MICT, Inc. (Nasdaq: MICT) (“MICT” or the “Company”), today announced that it received written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance
RHEA-AI
neutral
05/23/22 6:45 AM
NYSE, Nasdaq : PFE, BNTX
covid-19
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Pfizer Inc. and BioNTech SE today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/ 3 trial evaluating a third 3- µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. This descriptive analysis was based on 10 symptomatic COVID-19 cases identified from seven days...
RHEA-AI
positive
05/23/22 6:45 AM
Nasdaq : BNTX
covid-19
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use Authorization The third 3-µg dose was well-tolerated among 1,678 children under 5 years of age with a safety profile similar to placebo Vaccine efficacy of 80.3% was
RHEA-AI
positive
05/20/22 12:21 PM
NYSE : RAD
covid-19high short
COVID-19 Boosters Now Available at Rite Aid and Bartell Drugs Locations for Eligible Children Ages 5 – 11
Rite Aid today announced it will begin administering a booster dose of Pfizer’ s COVID-19 vaccine at select locations for eligible children ages 5 to 11, following approval by the Centers for Disease Control and Prevention and the Food and Drug Administration on Thursday. Bartell Drugs, owned by Rite Aid Corporation, will also begin administering boosters to...
RHEA-AI
neutral
05/19/22 8:00 AM
Nasdaq : IMNM
covid-19low float
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
Immunome, Inc., a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the Omicron variant of SARS-CoV-2 when tested in vivo in hamsters.
RHEA-AI
neutral
05/18/22 8:05 AM
Nasdaq : RGC
covid-19low float
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
Regencell Bioscience Holdings Limited today announced the results from an analysis of a total of 51 individuals enrolled in its additional E valuation and A ssessment of RGC-COV19 TM T CM through a H olistic approach efficacy trial conducted by Regencell Bioscience Asia Limited of its novel COVID-19 oral TCM candidate RGC-COV19 TM. Following the EARTH-B...
RHEA-AI
neutral
05/18/22 6:39 AM
NYSE : LH
covid-19
Labcorp Receives Emergency Use Authorization for First Non-Prescription At-Home Collection Kit for Combined COVID-19, Flu and RSV Detection
Labcorp, a leading global life sciences company, today announced the receipt of Emergency Use Authorization from the U.S. Food and Drug Administration for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus, a common but contagious respiratory virus often seen in children.
RHEA-AI
neutral
05/17/22 11:40 AM
NYSE, Nasdaq : PFE, BNTX
covid-19
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
EUA is based on data that show children 5 through 11 years of age had a robust immune response with a favorable safety profile following a 10- µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine at a time when Omicron was the prevalent variant Children 5 through 11 years of age now authorized to receive a booster dose at least five months after the second...
RHEA-AI
neutral
05/16/22 4:09 PM
AMEX : SSY
earningscovid-19low float
SunLink Health Systems, Inc. Announces Fiscal 2022 Third Quarter Results and COVID-19 Update
SunLink Health Systems, Inc. today announced a loss from continuing operations of $934,000 for its third fiscal quarter ended March 31, 2022 compared to a loss from continuing operations of $473,000 for the third fiscal quarter ended March 31, 2021. Provider Relief Funds of $106,000 were reported as income in the quarter ended March 31, 2022 compared to...
RHEA-AI
negative
05/11/22 7:00 AM
Nasdaq : AKTX
conferencescovid-19
Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American Thoracic Society
RHEA-AI
neutral
05/10/22 8:30 AM
Nasdaq : RDI
covid-19low float
Reading International Reports First Quarter 2022 Results and COVID-19 Business Update
Reading International, Inc., an internationally diversified cinema and real estate company with operations and assets in the United States, Australia, and New Zealand, today announced its results for the first quarter ended March 31, 2022. “With respect to our real estate business, we are encouraged by the continued improvement in our portfolio over the first...
RHEA-AI
neutral
05/02/22 9:00 AM
OTC : TSOI
clinical trialcovid-19
Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell™ Universal Donor Stem Cell Drug
Therapeutic Solutions International announced today the launching of a double-blind, randomized, placebo controlled, multi-center, multi-nation, clinical trial of 128 patients with COVID-19 associated lung failure. The study will be comprised of two groups, JadiCell™ treatment group and control group. “The launch of this clinical trial is a historical step...
RHEA-AI
very positive